CN101386829B - Avid kyowamycin genetic engineering bacterium and use thereof - Google Patents
Avid kyowamycin genetic engineering bacterium and use thereof Download PDFInfo
- Publication number
- CN101386829B CN101386829B CN2008102245332A CN200810224533A CN101386829B CN 101386829 B CN101386829 B CN 101386829B CN 2008102245332 A CN2008102245332 A CN 2008102245332A CN 200810224533 A CN200810224533 A CN 200810224533A CN 101386829 B CN101386829 B CN 101386829B
- Authority
- CN
- China
- Prior art keywords
- frr
- gene
- avrmectin
- avid kyowamycin
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a genetic engineering bacterium capable of improving the yield of abamectin, which is a recombinant bacterium over-expressed by ribosome circular factors obtained by the introduction of frr genes of the encoded ribosome circular factors in acitretin streptomycete into the acitretin streptomycete through an expression vector. The genetic engineering bacterium can be directly used for fermentation production of the abamectin and for improving the fermentation unit of the abamectin and reducing the production cost.
Description
Technical field
The present invention relates to microbial fermentation and genetically engineered field, be specifically related to a kind of genetic engineering bacterium and construction process and its application in producing Avrmectin that can improve Avrmectin output.
Background technology
Avrmectin is the 16-membered ring macrolides microbiotic of one group of efficient insecticide producing when being fermented by Avid kyowamycin (Streptomyces avermitilis), its natural product has eight components (A1a, A1b, A2a, A2b, B1a, B1b, B2a, B2b), wherein the insecticidal activity of B1 component is the strongest, is applied in the agriculture production mainly as sterilant, almost anti-all nematode and arthropodss relevant with agricultural.The mechanism of action of Avrmectin is different with the conventional chemical sterilant, they do not suppress Pseudocholinesterase, also arrestin matter synthetic not, but the activator of the parasitic nerve conduction medium γ-An Jidingsuan of nematode and arthropods class (GABA), thereby the nerve impulse conduction between the blocking-up nematode neurone, between arthropods nerve ending and myocyte causes death the parasite paralysis.And Mammals peripheral nerve conduction mediator is a vagusstoff, the nerve of making the conduction mediator with GABA exists only in central nervous system, under the normal dosage that uses, because mammiferous hemato encephalic barrier effect, cause medicine very low in the concentration that central nervous system distributes, be not enough to cause the release of GABA, so very little to mammiferous toxicity, selectivity is high.Because Avrmectin has unique mechanism of action, be difficult for making insect to produce resistance and crossed resistance, extremely safe to crop, killed natural enemies does not help keeping ecological balance, and easily degraded, noresidue, people, animal and environment there is tight security, make it to become the wonderful work of biological pesticide, be recommended as public nuisance-free agricultural chemicals, have boundless market outlook and using value by China Ministry of Agriculture.At present, Avrmectin has been realized industrialization at home, has obtained huge economic and social benefit.But it is low that the production bacterial strain of China's Avrmectin also exists fermentation unit, problems such as production cost height.How improving the output of Avrmectin, reduce production costs, is Eternal Theme in the Avrmectin research.Therefore, transform Avid kyowamycin to improve the output of Avrmectin, have great importance by genetic engineering means.
The ribosome cycle factor (RRF, ribosome recyling factor) extensively be present in the bacterium, its function is to finish the final step of protein synthesis in the albumen building-up process with elongation factor (EF-G) the synergy catalysis of responsible transposition---the disintegration of rrna mixture behind the translation termination.In addition, RRF has also kept the fidelity of translation in the extension process of peptide chain.The present invention attempts utilizing the overexpression of the ribosome cycle factor in Avid kyowamycin to improve the output of Avrmectin.
Summary of the invention
The genetic engineering bacterium that the purpose of this invention is to provide a kind of Avid kyowamycin, the output of comparing its Avrmectin with its starting strain is improved.The present invention also aims to provide the construction process of described genetic engineering bacterium.
Genetic engineering bacterium of the present invention is the frr gene of the ribosome cycle factor of coding in the Avid kyowamycin to be introduced the ribosome cycle factor that obtains in the Avid kyowamycin by expression vector cross the reorganization bacterium of expression.
The present invention provides a kind of method that makes up above-mentioned engineering bacteria for achieving the above object, its at first with the frr gene clone of the ribosome cycle factor of coding in the Avid kyowamycin in expression vector, again this expression vector is introduced Avid kyowamycin and is obtained the reorganization bacterium.
Described expression vector can be integrated expression vector or high copy number plasmid expression vector.
Specifically can adopt following method to make up engineering bacteria, frr gene and himself promotor with the ribosome cycle factor of coding (RRF) in the pcr amplification Avid kyowamycin, make up the multiple copied or the integrated expression plasmid of frr gene respectively, and the recombinant plasmid that builds is transformed into respectively in the Avid kyowamycin bacterial strain obtains the bacterium of recombinating; Or with the structure gene of frr gene in the pcr amplification Avid kyowamycin, it is placed under the erythromycin resistance gene strong promoter ermE*p, make up the multiple copied or the integrated expression plasmid of frr gene respectively, the recombinant plasmid that builds is transformed into respectively in the Avid kyowamycin bacterial strain obtains the bacterium of recombinating.
The carrier that sets out that is used to make up the frr expression vector can be any one intestinal bacteria-streptomycete shuttle vectors, as multiple copied plasmid vector pKC1139, pKC505, pIJ653, pIJ8154, or integrative plasmid carrier pSET152, pIJ8600, pIJ8660, be preferably pKC1139 and pSET152.
In an example of the present invention, be that the set out frr expression vector of vector construction is pFR1-1139 (containing frr gene and himself promotor) and pFR4-1139 (the frr gene places under the erythromycin resistance gene strong promoter ermE*p) with pKC1139; With pET152 is that the set out frr expression vector of vector construction is pFR1-152 (containing frr gene and himself promotor) and pFR4-152 (the frr gene places under the erythromycin resistance gene strong promoter ermE*p).
The method that the frr expression vector is transformed Avid kyowamycin is preferably the protoplast transformation method that PEG mediates, for improving transformation efficiency, can expression vector be transformed among the intestinal bacteria ET12567 of restriction modification effect defective earlier, therefrom extract the protoplastis that plasmid transforms Avid kyowamycin again; But also can adopt method commonly used in other bioengineering field, for example electrotransformation, conjugal transfer method etc.
The starting strain that is used to make up the reorganization bacterium can be the bacterial strain of any one Avid kyowamycin, is preferably the superior strain of Avrmectin.
The reorganization Avid kyowamycin genetic engineering bacterium that the present invention makes up can be directly used in the fermentative production of Avrmectin, the output of Avrmectin is improved, thereby reduce production costs.
Description of drawings
Fig. 1 contains the recombinant plasmid pFR1-1139 (Figure 1A) of frr gene and himself promotor and the plasmid map of pFR1-152 (Figure 1B); Fig. 2 is the recombinant plasmid pFR4-1139 (Fig. 2 A) that contains frr gene and erythromycin resistance gene strong promoter and the plasmid map of pFR4-152 (Fig. 2 B);
Fig. 3 is the abamectin fermented unit of Avid kyowamycin wild type strain ATCC31267 and different transformants thereof;
Fig. 4 is the abamectin fermented unit of Avid kyowamycin GB-165 and different transformants thereof;
Fig. 5 is the abamectin fermented unit of Avid kyowamycin 76-02-e and different transformants thereof;
Fig. 6 crosses the abamectin fermented unit graphic representation of expression strain ATCC31267 (pFR1-1139) and ATCC31267 for frr;
Fig. 7 crosses the thalli growth curve of expression strain ATCC31267 (pFR1-1139) and ATCC31267 for frr.
Embodiment
Following examples further specify content of the present invention, but should not be construed as limitation of the present invention.Without departing from the spirit and substance of the case in the present invention, modification or replacement to the inventive method, step or condition are done all belong to scope of the present invention.
If do not specialize the conventional means that used technique means is well known to those skilled in the art among the embodiment.
The structure of embodiment 1, frr expression vector
One, the construction of recombinant plasmid that contains frr gene and himself promotor
1, contains the amplification of the frr gene of self promotor
The design primer, be used for pcr amplification and be positioned at the frr gene [NC_003155.4 (3224362...3223805)] that contains self promotor on the Avid kyowamycin karyomit(e), upstream primer PrimerF1 (CCGACATGACCGCGATCAC) is positioned at frr upstream from start codon 300bp place, downstream primer PrimerR1 (CG
GAATTCGTCATGCGCATCGTACGTGG, band underscore base is a restriction enzyme EcoRI recognition site) being positioned at 150bp place, frr terminator codon downstream, amplified production should be 976bp.
Total DNA with Avid kyowamycin wild type strain ACTT31267 is a template, and PrimerF1 and Primer R1 are primer, carry out pcr amplification, and amplification condition is 95 ℃, 4min; (95 ℃, 1min; 60 ℃, 1min; 72 ℃, 1min) * 25 circulation; 72 ℃, 10min.Amplified production is carried out agarose gel electrophoresis detect, a specific amplified band is arranged at about 1kb place.
2, the structure of recombinant plasmid pFR1-1139 and pFR1-152
Reclaim test kit with DNA and reclaim pcr amplification product, be connected with T carrier pMD18-T (TaKaRa company), show through the order-checking comparison, the fragment that is increased is really for containing the frr gene of self promotor.The T carrier that will contain the frr gene is cut through BamHI and HindIII enzyme, reclaim the frr fragment of 1008bp, this fragment is connected to pIJ2925 carrier (the Janssen G R that cuts through BamHI and HindIII enzyme, and Bibb M J.Derivatives of pUC18that have BglII sites flanking a multiple cloningsite and that retain ability to identify recombinant clones by visualscreening of Escherichia coli colonies.Gene, 1993,124:133-134), called after pFR1-2925, enzyme is cut checking.To verify that then correct pFR1-2925 cuts with BglII and EcoRI enzyme, reclaim the frr fragment of about 1020bp.With this fragment respectively with carrier pKC1139 (the Bierman M that cuts through BamHI and EcoRI enzyme, Logan R, O ' Brien K, etal.Plasmid cloning vectors for the conjugal transfer of DNA fromEscherichia coli to Streptomyces spp.Gene, 1992,116:43-49) link to each other, connect the product competent cell (TaKaRa company) of transformed into escherichia coli DH5 α respectively with the carrier pSET152 (the same pKC1139 of reference) that cuts through same enzyme.Extract from transformant that plasmid carries out PCR and enzyme is cut checking, with correct recombinant plasmid called after pFR1-1139 and pFR1-152 respectively.PFR1-1139 is the plasmid of multiple copied, and pFR1-152 is an integrative plasmid, and they all have frr gene and himself promotor.The plasmid map of pFR1-1139 and pFR1-152 as shown in Figure 1.
Two, the construction of recombinant plasmid that contains frr gene and erythromycin resistance gene strong promoter
1, the amplification of frr structure gene
The design primer, being used for increases to be positioned at contains ribosome bind site (ribosome binding site, frr structural gene sequence RBS), upstream primer Primer F4 (GA on the Avid kyowamycin karyomit(e)
AGATCTCCTACTCAAGACACGCAGGAG, band underscore base is a restriction enzyme BglII recognition site) be positioned at frr upstream from start codon 20bp place, downstream primer Primer R4 (CCC
AAGCTTGTCATGCGCATCGTACGTGG, band underscore base is a restriction enzyme HindIII recognition site) being positioned at 120bp place, frr terminator codon downstream, amplified production should be 700bp.
Total DNA with Avid kyowamycin wild type strain ACTT31267 is that template, PrimerF4 and Primer R4 are primer, carries out pcr amplification, and amplification condition is with " one " in the present embodiment.Amplified production is carried out electrophoresis detection, an amplified band is arranged at the 700bp place.
2, the structure of recombinant plasmid pFR4-1139 and pFR4-152
Reclaim amplified production, it is connected with T carrier pMD18-T (TaKaRa company), show that through the order-checking comparison fragment that is increased is not really for containing the frr structure gene that promotor contains ribosome bind site.Cut the T carrier that contains frr structure gene with BglII and HindIII enzyme, reclaim the frr structure gene fragment of 700bp, this fragment is connected on the pIJ117 carrier that contains erythromycin resistance gene strong promoter (ermE*p) that BamHI and HindIII enzyme are cut (the BglII fragment that will contain ermE*p is inserted into to make up on the corresponding restriction enzyme site of pIJ2925 and forms), get recombinant plasmid pFR4-117, enzyme is cut evaluation.Then correct pFR4-117 is cut with the BglII enzyme, reclaim the ermE*p+frr fragment of about 1kb, this fragment is linked to each other with the carrier pSET152 that cuts through same enzyme with the carrier pKC1139 that cuts through the BamHI enzyme respectively, connect product transformed into escherichia coli DH5 α respectively.Extract from transformant that plasmid carries out PCR and enzyme is cut checking, with correct recombinant plasmid called after pFR4-1139 and pFR4-152 respectively.PFR4-1139 is the plasmid of multiple copied, and pFR4-152 is an integrative plasmid, and the frr structure gene in these two plasmids all places under the erythromycin resistance gene strong promoter ermE*p.The plasmid map of pFR4-1139 and pFR4-152 as shown in Figure 2.
The conversion of embodiment 2, recombinant plasmid
Made up four kinds of frr expression of gene plasmid vectors altogether by embodiment 1, be respectively pFR1-1139, pFR1-152, pFR4-1139 and pFR4-152, original plasmid in contrast is pKC1139 and pSET152.Now the characteristics of these six kinds of plasmids are made brief description (table 1).
Table 1 contains the characteristics of the recombinant plasmid and the original plasmid of frr gene
Owing to there is very strong restriction modification effect in the Avid kyowamycin, directly transform Avid kyowamycin with the plasmid of carrying from E.coliDH5 α, transformation efficiency is extremely low, sometimes even can not get transformant.And use plasmid from the recipient bacterium E.coli ET12567 of modification without limits, its transformation efficiency obviously improves.Therefore, the recombinant plasmid and the control plasmid that build are transformed into earlier E.coli ET12567 (Kieser T respectively, Bibb M J, Buttner M J, etal.Practical Streptomyces Genetics, 2000, Norwich:The John InnesFoundation.) obtaining non-methylated DNA, and then transforms the protoplastis of Avid kyowamycin with non-methylated plasmid DNA in.
This example has selected for use three kinds of different Avid kyowamycin bacterial strains to do the bacterial strain that sets out: ATCC31267, GB-165 and 76-02-e.ATCC31267 is the Avid kyowamycin wild type strain, produces the grey spore; GB-165 (Cai Yujuan. produce the research of green spore Avid kyowamycin genetic modification and fermentation condition. master thesis, 2006, Beijing: the Avid kyowamycin bacterial strain that only produces Avrmectin B component that China Agricultural University) to be this laboratory obtain through mutagenesis and genetic engineering means, produce green spores; 76-02-e (Guo Weiqun. the seed selection of Avrmectin superior strain and Optimizing Conditions of Fermentation. master thesis, 2007, Beijing: be this laboratory strain Avrmectin superior strain that wheel mutagenesis obtains through how China Agricultural University), only produce a spot of spore.The protoplastis for preparing these three kinds of Avid kyowamycin bacterial strains, transform protoplastis with the plasmid that from E.coli ET12567, extracts, be applied on the RM14 flat board of the not added with antibiotic that has dried up, behind 28 ℃ of cultivation 16-20h, on flat board, be coated with the aqueous solution that 1mL contains 1000 μ g apramycins, continue to cultivate 7-10 days at 28 ℃, the bacterium colony that grows is transformant.Because the transformant of Avid kyowamycin does not produce spore on the RM14 regeneration culture medium,, cultivate for 28 ℃ and recovered to produce spore in 7 days so three transformants of each picking are inoculated on the YMS flat board that contains 10 μ g/mL apramycins.Transformant carries out next step fermentation research after plasmid extraction and PCR checking correctly.
The preparation of colibacillary conversion in the present embodiment, Avid kyowamycin protoplastis and method for transformation, RM14 and YMS culture medium preparation referring to the Master's thesis of Cai Yujuan (Cai Yujuan. produce the research of green spore Avid kyowamycin genetic modification and fermentation condition. master thesis, 2006, Beijing: China Agricultural University).
The fermentation research of embodiment 3, transformant
One, the fermentation research of ATCC31267 and transformant thereof
1. the shake flask fermentation of Avid kyowamycin
Seed culture medium: Zulkovsky starch 30g, malt extract 2g, soy peptone 2g, CoCl
26H
2O5mg, adding distil water transfer pH to 7.0-7.2 to 1L.
Fermention medium: Zulkovsky starch 50g, yeast powder 12g, MgSO
47H
2O0.5g, K
2HPO
43H
2O0.5g, KCl4g; CaCO
32g, CoCl
26H
2O5mg, adding distil water transfer pH to 7.0-7.2 to 1L.
Avid kyowamycin wild type strain ATCC31267 and different transformants thereof are inoculated in the seed culture medium (loading amount is the 100mL/500mL triangular flask) grow abundant spore on the YMS substratum after, 28 ℃ of shaking tables are cultivated 24 hours (rotating speed 180rpm, eccentricity 2.5cm).Be inoculated in the fermention medium (loading amount is the 50mL/300mL triangular flask) by 5% inoculum size, cultivate 10 days (rotating speed 250rpm, eccentricity 2.5cm) for 28 ℃, put bottle, with the fermentation unit of HPLC method mensuration Avrmectin, the result as shown in Figure 3.
2, the HPLC of tunning analyzes
1) sample preparation: get the 1.0mL fermented liquid, add 4.0mL methyl alcohol, soak more than 30 minutes, every vibration in 10 minutes once, centrifugal 10 minutes of 4000rpm gets the analysis of supernatant liquor sample introduction;
2) HPLC analysis condition: C
18Reversed-phase column, column length 150mm, column internal diameter 4.6mm, 40 ℃ of column temperatures, moving phase is methyl alcohol: water (85:15), flow velocity 1.0mL/min, sampling volume 10 μ L, wavelength is 246nm.
The fermentation result of Fig. 3 shows, the conversion of control plasmid pKC1139 and pSET152 is little to the yield effect of Avrmectin, and the abamectin fermented unit that contains the ATCC31267 transformant of frr expression vector compares all obviously increase with starting strain, two kinds of abamectin fermented units that contain high copy recombinant plasmid transformed have increased 3-3.7 doubly, and two kinds of abamectin fermented units that contain integrated recombinant plasmid transformed have increased 71%-86%.Can determine the dosage effect of frr gene in ATCC31267 thus.The increase that contains frr gene plasmid copy number causes the increase of frr expression amount, and the frr gene pairs Avrmectin synthetic promoter action of high copy is better than the frr gene of low copy.Relatively be used to express of the influence of two kinds of different promoters of frr gene to Avrmectin output, as can be seen, the abamectin fermented unit that contains two kinds of transformants of frr gene self promotor all is higher than two kinds of transformants that contain erythromycin resistance gene strong promoter (ermE*p), may be when expressing frr erythromycin resistance gene strong promoter (ermE*p) be not better than self promotor of frr gene.
Two, the fermentation research of GB-165 and transformant thereof
Shake flask fermentation and HPLC analytical procedure are with " one " in the present embodiment, and difference is that used fermention medium is fermention medium G: Zulkovsky starch 95g, peanut protein powder 25g, cottonseed protein 7g, maltose 3g, MgSO
47H
2O0.3g, CoCl
26H
2O7.5mg, (NH
4)
2SO
40.1g, CaCO
31g, K
2HPO
43H
2O0.3g, ZnSO
47H
2O2mg, adding distil water transfer pH to 7.0-7.2 to 1L.
From the fermentation result of Fig. 4 as can be seen, frr gene crossing in GB-165 expressed and can be promoted the synthetic of Avrmectin equally, and the frr gene pairs Avrmectin synthetic promoter action of high copy is better than the frr gene of low copy.
Equally, the abamectin fermented unit of two kinds of transformants that contains frr gene self promotor is all a little more than two kinds of transformants that contain erythromycin resistance gene strong promoter (ermE*p), shows that once more erythromycin resistance gene strong promoter (ermE*p) is not better than self promotor of frr gene when expressing frr.
Three, the fermentation research of 76-02-e and transformant thereof
Shake flask fermentation and HPLC analytical procedure are with " one " in the present embodiment, and difference is that the spore of 76-02-e is not abundant, and the seed culture time is 40-46 hour, used fermention medium is fermention medium E: W-Gum 120g, groundnut meal 26g, soybean cake powder 2g, yeast powder 8g, (NH
4)
2SO
40.25g, CoCl
26H
2O25mg, MnSO
44H
2O30mg adds tap water to 1L, the pH nature.
The fermentation result of Fig. 5 shows, in superior strain 76-02-e, expresses the frr gene and still can promote the synthetic of Avrmectin, and be the frr gene that the high frr gene pairs microbiotic synthetic promoter action that copies is better than low copy equally.
Different with the GB-165 transformant with ATCC31267 is, the output that contains Avrmectin in the 76-02-e transformant of erythromycin resistance gene strong promoter ermE*p may be because 76-02-e is different with ATCC31267 and GB-165 on the frr gene expression regulation a little more than the transformant that contains frr gene self promotor.
The study on the stability of embodiment 4, engineering strain
The engineering strain of constructed frr gene overexpression is transferred five times on the YMS inclined-plane continuously, find that this bacterial strain is identical on morphological specificity and cultural characteristic with starting strain, growth conditions is good, and proterties is stable.Engineering strain through transferring after five times carries out shake flask fermentation again, and considerable change does not all take place HPLC check Avrmectin output, illustrate that the engineering bacteria of structure is stable.
Present embodiment has compared the changing conditions of frr gene overexpression strains A TCC31267 (pFR1-1139) and starting strain ATCC31267 Avrmectin output and dry cell weight in the shake flask fermentation process.
The HPLC analytical procedure of shake flask fermentation and Avrmectin is with " one " among the embodiment 3, difference is to select for use the fermention medium II fermentation culture thalline of solubility, this is owing to contain insoluble components in the Avid kyowamycin fermention medium, is unfavorable for the accurate mensuration of dry cell weight.Different time is taken a sample, and measures the fermentation unit (Fig. 6) and the dry cell weight (Fig. 7) of Avrmectin respectively.
Fermention medium II: Zulkovsky starch 70g, yeast enzymolysis powder 16g, MgSO
47H
2O0.5g, K
2HPO
43H
2O0.5g, KCl4g, CoCl
26H
2O5mg, adding distil water transfer pH to 7.0-7.2 to 1L.
The mensuration of dry cell weight: with the 50ml filtering fermentation liquor, thalline is cleaned with distilled water, dries to constant weight, claims dry cell weight.
By Fig. 6 and Fig. 7 as can be known, Avrmectin output and the dry cell weight of ATCC31267 (pFR1-1139) are higher than ATCC31267 always, show that expression frr gene can promote thalli growth.As seen, in the frr gene overexpression bacterial strain raising reason of Avrmectin output some give the credit to the raising of thalline biomass in the fermented liquid, some reason may be the expression amount that the overexpression of frr gene has improved positive regulating gene aveR in the Avrmectin biological synthesis gene cluster and Avrmectin biosynthesizing relevant enzymes, but this supposition awaits further confirming by experiment.
The sequence explanation:
SEQ ID No.1﹠amp; 2 primers F 1 and R1 for amplification frr gene and promotor thereof, SEQ IDNo.3﹠amp; 4 primers F 4 and R4 for amplification frr gene.
Sequence table
＜110〉China Agricultural University
＜120〉a kind of Avid kyowamycin genetic engineering and application thereof
<130>KHP08112921.4
<160>4
<170>PatentIn?version3.5
<210>1
<211>19
<212>DNA
＜213〉artificial sequence
<400>1
<210>2
<211>28
<212>DNA
＜213〉artificial sequence
<400>2
<210>3
<211>29
<212>DNA
＜213〉artificial sequence
<400>3
<210>4
<211>29
<212>DNA
＜213〉artificial sequence
<400>4
Claims (8)
1. genetic engineering bacterium, it is the frr gene of the ribosome cycle factor of coding in the Avid kyowamycin to be introduced the ribosome cycle factor that obtains in the Avid kyowamycin by expression vector cross the reorganization bacterium of expression, and the carrier that sets out of wherein said expression vector is pKC1139, pKC505, pIJ653, pIJ8154, pSET152, pIJ8600 or pIJ8660.
2. engineering bacteria as claimed in claim 1 is characterized in that, described expression vector is integrating vector or high copy number plasmid carrier.
3. engineering bacteria as claimed in claim 1 is characterized in that, the promotor of frr gene is himself promotor or is promotor ermE*p in the described expression vector.
4. as each described engineering bacteria of claim 1～3, it is characterized in that the carrier that sets out of described expression vector is pKC1139 or pSET152.
5. as each described engineering bacteria of claim 1～3, it is characterized in that described expression vector is the pFR4-152 shown in the pFR4-1139 shown in the pFR1-1139 shown in Figure 1A, Fig. 2 A, the pFR1-152 shown in Figure 1B or Fig. 2 B.
6. the application of each described engineering bacteria of claim 1～3 in the preparation Avrmectin.
7. the application of the described engineering bacteria of claim 4 in the preparation Avrmectin.
8. the application of the described engineering bacteria of claim 5 in the preparation Avrmectin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102245332A CN101386829B (en) | 2008-10-20 | 2008-10-20 | Avid kyowamycin genetic engineering bacterium and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102245332A CN101386829B (en) | 2008-10-20 | 2008-10-20 | Avid kyowamycin genetic engineering bacterium and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101386829A CN101386829A (en) | 2009-03-18 |
| CN101386829B true CN101386829B (en) | 2010-10-20 |
Family
ID=40476504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008102245332A Expired - Fee Related CN101386829B (en) | 2008-10-20 | 2008-10-20 | Avid kyowamycin genetic engineering bacterium and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101386829B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101586133B (en) * | 2009-06-24 | 2012-01-04 | 张福志 | Abamectin batch fermentation optimizing process |
| CN103289945A (en) * | 2013-05-08 | 2013-09-11 | 中国计量学院 | Frr expression reinforced recombined streptomyces diastatochromogenes, as well as construction method and use |
| CN104480057A (en) * | 2014-12-04 | 2015-04-01 | 江南大学 | Construction method and application of L-isoleucine producing genetically engineered bacteria |
| CN104531598B (en) * | 2015-01-08 | 2018-01-16 | 齐鲁工业大学 | It is a kind of to recombinate streptomycete, its construction method and the method for improving antibiotic yield |
| CN108728391A (en) * | 2018-05-24 | 2018-11-02 | 中国农业大学 | Avermectin produces bacterial strain and its production method |
| CN108841768A (en) * | 2018-05-24 | 2018-11-20 | 中国农业大学 | The method that avermectin produces bacterial strain and improves avermectin yield |
| CN112342203B (en) * | 2020-10-29 | 2021-12-28 | 四川轻化工大学 | Application of ribosome sigma factor, mutant thereof and protein obtained by encoding to increase yield of lipstatin |
-
2008
- 2008-10-20 CN CN2008102245332A patent/CN101386829B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101386829A (en) | 2009-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101386829B (en) | Avid kyowamycin genetic engineering bacterium and use thereof | |
| US10047363B2 (en) | NRPS-PKS gene cluster and its manipulation and utility | |
| CN101613712B (en) | Method for improving abamectin and/or ivermectin output and bacterial strain production thereof | |
| US20140105862A1 (en) | Streptomyces microflavus strains and methods of their use to control plant diseases and pests | |
| CN102191208A (en) | Gene engineering bacteria capable of highly producing pleocidin and preparation method thereof | |
| CN104974974A (en) | Saccharopolyspora spinosa high-pleocidin-yield engineering strain and application thereof | |
| CN104531598B (en) | It is a kind of to recombinate streptomycete, its construction method and the method for improving antibiotic yield | |
| CN100562565C (en) | The gene recombined engineering bacterium of Spinosad microbial inoculum | |
| Srinivasulu et al. | Construction of asm2 deletion mutant of Actinosynnema pretiosum and medium optimization for ansamitocin P-3 production using statistical approach | |
| CN101914482A (en) | Isovalerylspiramycin I component high-content high-yield genetic engineering bacteria | |
| CN103834605A (en) | Avermectin producing bacteria and preparation method and application thereof | |
| CN110564718B (en) | Method and strain for screening high-yield amphotericin B-tubercle streptomycete by high-throughput mutagenesis | |
| CN103060364A (en) | A recombinant streptomyces lydicus producing natamycin, a construction method and applications thereof | |
| CN103626855B (en) | A kind of albumen relevant to Wuyiencin biosynthesizing and encoding gene thereof and application | |
| CN102162003B (en) | Method for improving yield of avermectins and producing strain thereof | |
| CN104928313B (en) | Application of the Avid kyowamycin rex genes in AVM yield is improved | |
| CN104263738A (en) | Biosynthesis gene cluster of FAS II inhibitor ABX | |
| CN101475944B (en) | Promoter replacement method for improving Bacillus amyloliquefaciens yield | |
| CN105087507B (en) | A kind of integrase and its application in transformation thorn saccharopolyspora strain | |
| CN110577921B (en) | Recombinant streptomyces tuberculatus for producing amphotericin B and application thereof | |
| CN105969714A (en) | Xiamenensis mycin high-producing strain and culture medium and application thereof | |
| CN110343650A (en) | A kind of recombination streptomyces nodocus of high yield amphotericin B and its application | |
| CN102517321A (en) | Optimized production method of abamectin | |
| CN111454975B (en) | Application of ECH gene related to spinosad | |
| CN107557376B (en) | Engineering bacterium for producing lasalocid and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20090318 Assignee: Qilu Pharmaceutical (Inner Mongolia) Co., Ltd. Assignor: China Agricultural University Contract record no.: 2013990000132 Denomination of invention: Avid kyowamycin genetic engineering bacterium and use thereof Granted publication date: 20101020 License type: Exclusive License Record date: 20130402 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101020 Termination date: 20151020 |
|
| EXPY | Termination of patent right or utility model |